Karboplatin Accord

Carboplatin, the active ingredient in Karboplatin Accord, is a platinum compound presented as an injectable solution for intravenous use. It is employed in the treatment of various solid tumours, particularly in adult oncology patients.\n\nGNH India supplies Karboplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Carboplatin is used in chemotherapy regimens targeting several malignant disease groups.\n\n- Ovarian cancer: improves response rates when combined with taxanes in first‑line therapy.\n- Non‑small cell lung cancer: used with paclitaxel or gemcitabine for advanced disease.\n- Head and neck cancer: part of concurrent chemoradiation protocols to enhance local control.\n- Bladder cancer: administered as part of combination regimens for muscle‑invasive disease.\n- Testicular cancer: employed in salvage therapy for refractory germ‑cell tumours.

Carboplatin may cause a range of adverse reactions, from mild to severe.\n\nCommon Side Effects:\n- Nausea and vomiting: transient gastrointestinal upset.\n- Myelosuppression: reduced white blood cells, platelets, and red cells.\n- Fatigue: generalized tiredness during treatment cycles.\n- Electrolyte disturbances: especially low magnesium levels.\n- Mild renal function changes: transient increase in serum creatinine.\n\nSerious or Rare Side Effects:\n- Severe neutropenia or thrombocytopenia: increased infection or bleeding risk.\n- Anaphylactic reactions: rare hypersensitivity to the infusion.\n- Ototoxicity: potential hearing loss at high cumulative doses.\n- Pulmonary toxicity: interstitial pneumonitis in rare cases.\n- Secondary malignancies: rare risk of therapy‑related leukemia.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for toxicity.\n\n- Renal function: evaluate baseline creatinine clearance and adjust dose if impaired.\n- Hematologic status: obtain complete blood count; postpone treatment if severe cytopenias are present.\n- Hydration: ensure adequate fluid intake to support renal clearance.\n- Concomitant ototoxic drugs: avoid or monitor when used together.\n- Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with obstetric specialist.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Carboplatin may interact with other agents, altering efficacy or safety.\n\nMajor Interactions (Avoid):\n- Nephrotoxic drugs (e.g., cisplatin, aminoglycosides): increase risk of renal injury.\n- Myelosuppressive agents (e.g., high‑dose cyclophosphamide): potentiate bone‑marrow suppression.\n\nModerate Interactions (Monitor Closely):\n- Radiotherapy: may enhance tissue toxicity when combined.\n- Antiemetics (e.g., ondansetron): monitor for QT prolongation.\n- NSAIDs: may affect renal function; assess renal parameters regularly.